Fundamental Analysis of Tatva Chintan Pharma Chem Ltd. - Growth / Value Index



TATVA - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.56
   Very Expensive - Price to Intrinsic Value of 3.59
   Price to Earning Ratio is 444.66 and EV to EBITDA is 77.75 suggesting that it is very expensive
   Price to Book Ratio of 4.31 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ Screener/ About
Price to Earning 465.10 277.52 107.40 %    
Price to Book 4.51 2.14 0 % 2.25    
Price to Sales 8.45 4.14 -86.04 %    
Enterprise Value to EBITDA Multiple 44.06 -89.40 %    


TATVA - Profitability Highlights

Profitability Analysis

   Piotroski F Score - Good Value of 7.0
   Net profit has jumped from negative to positive
   Excellent QoQ /QoQ FY EPS growth
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Very Low Dividend Yield of 0 %
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ Screener/ About
Return On Equity 0.970 0.773 0 % 0.900    
Return On Asset 0.872 0.683 0 % 0.795    
Net Profit Margin 1.82 1.49 288.74 % 5.69    
Operating Profit Margin 28.06 1.37 -98.63 % 14.83    
EBITDA Margin 10.46 9.55 33.71 % 15.81    


Highlights
Market Cap33270.52 M
Enterprise Value33520.66 M
Price/Book TTM4.51
Outstanding Share23392.06 K
Float/ Outstanding Share28.01%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No9.65
Peter Lynch Ratio0
Piotroski F Score7.00                  
Altman Z Score21.74                  
Sloan Ratio0.055
Peter Lynch Fair Value0


TATVA - Growth Highlights

Growth Analysis

   Short term positive trend in total sale and net profit
   STRONG JUMP IN NET SALE : YoY growth
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Very Poor Score of 14.58
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 394.11 (Cr) 358.39 % 8.34 %
Gross Profit 174.07 (Cr) % 16.62 %
EBITDA 41.23 (Cr) 512.92 % 90.91 %
Net Profit 7.16 (Cr) 965.15 % 545.63 %
EPS 3.06 971.43 % NA


TATVA - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 87.50
   Altman Z Score of 20.84 suggests good Stability
   Company is unable to generate enough free cash to support the business.
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ Screener/ About
Debt to Equity Ratio 0.0493 0 % 0.0493    
Cash Ratio 0.147 0 %    
Quick Ratio 1.37 0 % 1.37    
Shareholders Equity 88.35 0 %    
Debt to EBITDA 0.996 0 %    


Historical Valuation Ratios of Tatva Chintan Pharma Chem Ltd.

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Tatva Chintan Pharma Chem Ltd.

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Tatva Chintan Pharma Chem Ltd.

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Tatva Chintan Pharma Chem Ltd.

Historical Solvency Ratios
Loading ...
Quick Overview of Fundamental Filters